2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CASPOFUNGIN Children's Oncology Group | Phase 3 | BB |
Fluconazole Children's Oncology Group | Phase 3 | BB |
Daunorubicin National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2 | B |
Fludarabine National Cancer Institute (NCI) | Phase 2 | B |
View all 18 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →